Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301597 · ClinicalTrials.gov registry record · Phase 2
NLA101 in Adults Receiving High Dose Chemotherapy for AML
A Phase 2 study, sponsored by Nohla Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT03301597: Clinical Trial Phase 2 study, sponsored by Nohla Therapeutics.
NCT03301597 is a Phase 2 study that was terminated before completion, run by Nohla Therapeutics. The registered enrollment target is 146 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03301597, a Phase 2 study, was terminated before completion, sponsored by Nohla Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
Interventions
- BIOLOGICAL NLA101
- DRUG Standard of Care (SOC) chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-03-18 |
| Phase | Phase 2 |
Why NCT03301597 stopped before completion
NCT03301597 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which NLA101 is the first listed.
NCT03301597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03301597 about?
NCT03301597 is a clinical study titled "NLA101 in Adults Receiving High Dose Chemotherapy for AML". Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
What is the current status of trial NCT03301597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2018-01-24. Estimated completion is 2019-03-18.
What interventions are being tested in trial NCT03301597?
The interventions under investigation include: NLA101 (BIOLOGICAL), Standard of Care (SOC) chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03301597?
This trial is sponsored by Nohla Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03301597's enrollment target sits among peer trials
146 496th of 2000 higher than 1,503 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI